AUSTRALIAN PRODUCT INFORMATION

ALPRIM
Trimethoprim

1 NAME OF THE MEDICINE
Trimethoprim

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Trimethoprim is a synthetic antibacterial.
It is a white, or yellowish-white powder, odourless or almost odourless. Practically insoluble in ether.
Each ALPRIM tablet contains trimethoprim 300 mg as the active ingredient.
For the full list of excipients, see section 6.1 List of excipients.

3 PHARMACEUTICAL FORM
The 9.5 mm tablets are white, normal convex, marked “TM/300” on one side and “G” on reverse.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS
Treatment of acute urinary tract infections caused by sensitive organisms.

4.2 DOSE AND METHOD OF ADMINISTRATION
Adults and Children over 12 years
One tablet daily for 7 days.
Children over 6 years
Half a tablet daily for 7 days.
Children under 6 years
There is no information available at present concerning the appropriate dose of ALPRIM in children under the age of 6 years.
Renal Failure
The use of trimethoprim in patients with creatinine clearance of less than 15 mL/minute is not recommended. If the creatinine clearance is between 15 and 30 mL/minute, a reduced dose should be considered.
In the treatment of acute urinary tract infection due to susceptible organisms it is not necessary to use ALPRIM for longer than 7 days.
To ensure maximal urinary concentration it may be advantageous to take the dose before bedtime. The dose may be taken with some food to minimise the possibility of gastrointestinal disturbance.

4.3 CONTRAINDICATIONS
ALPRIM should not be given to patients with a history of trimethoprim hypersensitivity.
Patients with severely impaired renal function (creatinine clearance less than 10 mL/min) should not be prescribed ALPRIM unless the plasma concentration of trimethoprim is monitored repeatedly during treatment.
ALPRIM should not be given to patients with severe haematological disorders or documented megaloblastic anaemia due to folate deficiency.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Care should be exercised in treating suspected folate deficient patients. Folate supplementation should be considered. Folinic acid (3 – 6 mg/day) as calcium folinate, may be administered without interfering with the antibacterial activity of trimethoprim.

**Electrolyte Abnormalities**

Close monitoring of serum electrolytes is advised in patients at risk of hyperkalaemia. These include older patients, those with renal impairment and those taking other medicines that are known to increase serum potassium (see sections 4.5 Interactions with Other Medicines and Other Forms of Interactions and 4.8 Adverse Effects (Undesirable Effects)).

**Use in Renal and Hepatic Impairment**

Trimethoprim may cause a significant, reversible increase in serum creatinine. Tubular secretion of creatinine is inhibited by trimethoprim. It should not be given in severe impairment unless blood concentrations can be monitored.

Trimethoprim should be used cautiously in patients with impaired renal or hepatic function.

**Use in the Elderly**

Care should be exercised in treating elderly patients.

**Paediatric Use**

See section 4.2 Dose and Method of Administration.

**Miscellaneous**

*Skin rash:* trimethoprim should be discontinued if a skin rash appears.

*Porphyria:* trimethoprim has been associated with acute attacks of porphyria and is considered unsafe in porphyria patients.

**Effects on Laboratory Tests**

Regular monthly blood counts are advisable when ALPRIM is given for long periods since there exists a possibility of symptomatic changes in haematological laboratory indices due to lack of available folate.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

There is the possibility of megaloblastic anaemia developing in patients prescribed trimethoprim whilst taking pyrimethamine for malarial prophylaxis.

**Warfarin**

Trimethoprim may potentiate the anticoagulant activity of warfarin though the precise mechanism is unclear. Careful control of anticoagulant therapy during treatment with trimethoprim is advisable.

**Phenytoin, Digoxin, Procainamide**

Trimethoprim may increase serum concentrations and potentiate the effect of phenytoin, digoxin and procainamide.

**Zidovudine, Zalcitabine, Lamivudine**

Trimethoprim has been reported to reduce the renal excretion and increase blood concentrations of zidovudine, zalcitabine and lamivudine.
**Dapsone**
Trimethoprim and dapsone increase each other’s serum concentration when given concomitantly.

**Rifampicin**
Rifampicin may decrease the trimethoprim concentration.

**Ciclosporin**
An increased risk of nephrotoxicity has been reported with use of trimethoprim or co-trimoxazole and ciclosporin.

**Diuretics**
In patients given trimethoprim who were also receiving diuretics, hyponatraemia has been reported.

**Bone Marrow Depression**
Use of trimethoprim with other depressants of bone marrow function may increase the likelihood of myelosuppression and there may be a particular risk of megaloblastic anaemia if it is given with other folate inhibitors, such as pyrimethamine or methotrexate.

Concomitant use of medicines known to increase serum potassium, such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers and potassium sparing diuretics may result in severe hyperkalaemia.

If ALPRIM is considered appropriate therapy in patients receiving other anti-folate drugs such as methotrexate, a folate supplement should be considered (see section 4.4 Special Warnings and Precautions for Use).

Cases of pancytopenia have been reported in patients taking trimethoprim in combination with methotrexate. Most of these patients were on long term methotrexate therapy, and/or predisposed to folate deficiency, and none of them were reported to have received a prophylactic folinic acid supplement (see section 4.4 Special Warnings and Precautions for Use).

### 4.6 FERTILITY, PREGNANCY AND LACTATION

**Effects on Fertility**
No data available.

**Use in Pregnancy**
Pregnancy Category: B3
Trimethoprim may interfere with folic acid metabolism and animal experiments have shown that administration of very high doses of trimethoprim during organ development may give rise to birth defects typical of folic acid antagonism. If trimethoprim is given during pregnancy, folic acid supplementation may be required.

**Use in Lactation**
Trimethoprim is excreted in human milk. When ALPRIM is administered to a nursing mother, alternative arrangements should be made for feeding the infant.

### 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person’s ability to drive and use machines were not assessed as a part of its registration.

### 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

The adverse effects encountered most often with trimethoprim are rash and pruritus. Other adverse effects reported involved the gastrointestinal and haematopoietic systems.
**Dermatologic Reactions**
Rash, pruritus and exfoliative dermatitis.
Rarely: erythema multiform, Steven-Johnson syndrome and toxic epidermal necrolysis.
At the recommended dose of 300 mg daily, the incidence of rash is 7.9%. These rashes were maculopapular, morbilliform, pruritic and generally mild to moderate, appearing 7 to 14 days after the initiation of therapy.

**Gastrointestinal Reactions**
Epigastric distress, nausea, vomiting and glossitis.

**Haematologic Reactions**
Thrombocytopenia, leucopenia, neutropenia, megaloblastic anaemia and methaemoglobinaemia.
Although an effect on folate metabolism is possible, interference with haematopoiesis occurs rarely at the recommended dosage. If any such change is seen, calcium folinate may be administered. Elderly patients may be more susceptible and a lower dosage may be advisable.

**Metabolism and Nutrition Disorders**
Hyperkalaemia, hyponatraemia.
Close supervision is recommended when trimethoprim is used in elderly patients, patients with renal impairment or patients taking high doses as these patients may be more susceptible to hyperkalaemia and hyponatraemia.

**Immune System Disorders**
Anaphylaxis and anaphylactoid reactions.

**Miscellaneous Reactions**
Fever, elevation of serum transaminases and bilirubin and increases in BUN and serum creatinine levels.

**Reporting Suspected Adverse Effects**
Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

### 4.9 OVERDOSE

**Acute**
Signs of acute overdosage with trimethoprim may appear following ingestion of 1 g or more of the drug and include nausea, vomiting, dizziness, headaches, mental depression, confusion and bone marrow depression (see Overdose, Chronic below).

**Treatment**
General supportive measures and the use of activated charcoal (where physicochemical appropriate) have generally been seen as acceptable recommendations. Acidification of the urine will increase renal elimination of trimethoprim. Peritoneal dialysis is not effective and haemodialysis only moderately effective in eliminating the drug.

**Chronic**
Use of trimethoprim at high doses and/or for extended periods of time may cause bone marrow depression manifested as thrombocytopenia, leucopenia and/or megaloblastic anaemia. If signs of bone marrow depression occur, trimethoprim should be discontinued and the patient should be given folinic acid as calcium folinate, 3 to 6 mg intramuscularly daily for three days, or as required to restore normal haematopoiesis.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5  PHARMACOLOGICAL PROPERTIES

5.1  PHARMACODYNAMIC PROPERTIES

Mechanism of Action
Trimethoprim blocks the formation of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the enzyme dihydrofolate reductase. Its affinity for the bacterial dihydrofolate reductase enzyme is much stronger than for the corresponding mammalian enzyme. Thus, trimethoprim selectively interferes with bacterial biosynthesis of nucleic acids and proteins.

Trimethoprim is an active in vitro against the common urinary tract pathogens.

Representative minimum inhibitory concentrations (MIC) for trimethoprim in susceptible organisms:

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Trimethoprim MIC mcg/mL (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Escherichia coli</em></td>
<td>0.05 – 1.5</td>
</tr>
<tr>
<td><em>Proteus mirabilis</em></td>
<td>0.5 – 1.5</td>
</tr>
<tr>
<td><em>Proteus sp. (indole positive)</em></td>
<td>0.5 – 5.0</td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em></td>
<td>0.5 – 5.0</td>
</tr>
</tbody>
</table>

It is not active against *Pseudomonas spp.*

Normal vaginal and faecal flora are the source of most pathogens causing urinary tract infections. It is therefore relevant to consider the suppressive effect of trimethoprim at these sites.

Concentrations of trimethoprim in vaginal secretions are consistently greater than those found simultaneously in the serum, being typically 1.6 times the concentration of simultaneously obtained serum samples.

Sufficient trimethoprim is excreted in the faeces to markedly reduce or eliminate trimethoprim susceptible organisms from the faecal flora.

*In vitro* resistance develops rapidly when susceptible bacteria are passed through increasing concentrations of the drug. However, following clinical use there have been conflicting reports on the development of resistance to trimethoprim when used alone. The possibility of increasing resistance to trimethoprim cannot at present be ruled out. Generally, resistance is more likely to occur in hospital than in domiciliary use. Plasmid mediated as well as chromosomal resistance to trimethoprim have been reported.

Microbiology, Susceptibility Tests

*Dilution or Diffusion Techniques*

Either quantitative (MIC) or breakpoint should be used following a regularly updated, recognised and standardised method (e.g. NCCLS). Standardised susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Immediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applications in body sites where the drug is physiologically concentrated or in situations where high dosage of the drug is used. This category also provides a buffer zone, which prevents small-uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected.
Note: the prevalence of resistance may vary geographically for selected species and local information on resistance is desirable, particularly when treating severe infections.

**Clinical Trials**
No data available.

### 5.2 PHARMACOKINETIC PROPERTIES

**Absorption**
Trimethoprim is rapidly absorbed following oral administration.

**Distribution**
Approximately 44% of the drug is protein bound in the blood.

**Metabolism**
Time to peak concentration in the circulation occur about 0.6 to 4 hours after an oral dose. Food decreases the area under the plasma concentration-time curve by approximately 20%. The half-life of trimethoprim ranges from 8 to 12 hours in the presence of normal renal function.

**Excretion**
In subjects receiving a single dose of 100 mg trimethoprim, the urinary concentration ranged from 30 to 160 mcg/mL, zero to 4 hours after the dose, and from 18 to 90 mcg/mL 8 to 24 hours after the dose. Increasing the dose of trimethoprim to 200 mg will double the urinary concentration.

Elimination is delayed in patients with renal insufficiency. The use of trimethoprim in patients with a creatinine clearance of less than 15 mL/minute is not recommended.

### 5.3 PRECLINICAL SAFETY DATA

**Genotoxicity**
No data available.

**Carcinogenicity**
No data available.

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 LIST OF EXCIPIENTS

ALPRIM tablets contain the following inactive ingredients: lactose monohydrate, povidone, sodium starch glycollate, purified talc and magnesium stearate.

#### 6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

#### 6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

#### 6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.
6.5 NATURE AND CONTENTS OF CONTAINER

Container type: blister pack

Pack sizes: 7 tablets

Some strengths, pack sizes and/or pack types may not be marketed.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical Structure

5-(3,4,5-trimethoxybenzyl)-pyrimidine-2, 4-diamine

Structural formula

Molecular formula: C_{14}H_{18}N_{4}O_{3}

Molecular weight: 290.3

CAS Number

738-70-5

Melting point about 200°C. Solubility 1:2500 of water, 1:300 in ethanol (96%), 1:55 of chloroform and 1:80 of methyl alcohol.

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 (Prescription Only Medicine)

8 SPONSOR

Alphapharm Pty Limited

Level 1, 30 The Bond

30 – 34 Hickson Road

Millers Point NSW 2000

ABN 93 002 359 739

www.mylan.com.au

9 DATE OF FIRST APPROVAL

06/04/1998
10 DATE OF REVISION
14/08/2018

Summary Table of Changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of New Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>Electrolyte abnormalities, impaired renal function, impaired hepatic function</td>
</tr>
<tr>
<td>4.5</td>
<td>Use of medicines which increase serum potassium</td>
</tr>
<tr>
<td>4.8</td>
<td>Revision of subheadings to exhibit information more correctly</td>
</tr>
</tbody>
</table>

alprim_pi\Aug18/01